Weekly Paclitaxel in Combination with Bevacizumab in Patients with Non-Squamous Non-Small Cell Lung Cancer Previously Untreated -A Phase II study-
Phase of Trial: Phase II
Latest Information Update: 01 Jul 2019
Price : $35 *
At a glance
- Drugs Bevacizumab (Primary) ; Paclitaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 27 Jun 2019 Status changed from active, no longer recruiting to completed.
- 26 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 23 Jul 2014 New trial record